EN 
FR 
Linearis Labs | About our work
Linearis Labs is expanding omics testing and discovery capabilities. Linearis Labs operates from our recently acquired 9000 sq ft (800m2) laboratory.
Linearis offers metabolomics profiling services. Services include both targeted and untargeted LC-MS measurements. High throughput procedures are also available to process thousands of samples. The analyses are carried out in a clinical grade environment.
We work with leaders in both AI and metabolomics to generate quantitative and actionable AI-friendly data as part of their AI pipelines. Some recent work involves omics signatures for COVID-19 and cancer. Linearis Labs couples high throughput technology and mass spectrometry to provide metabolomics analysis of blood plasma.
Linearis Labs couples high throughput technology and mass spectrometry to provide metabolomics analysis of minimal amounts of biological fluids for diseases including cancer, diabetes and antimicrobial resistance which have significant metabolomics components.
Using an AI pipeline, disease signatures are discovered and can provide actionable insights for several types of metabolomic diseases, improve effectiveness of therapeutic interventions, and prevent the emergence of resistance and side effects of treatments. Using an AI pipeline, disease signatures are discovered and can provide actionable insights
Linearis Labs offers metabolomics profiling services for biobanks using both a targeted 1300 metabolomic assay and untargeted LC-MS measurements.
Metabolomic Analysis
As metabolomics is closer to the phenotype, it provides a great advantage for biobanks to acquire metabolomics data.
Moreover, there is an expectation that multi-omics analyses will be required for better interpretation of the diseases under investigation.
The data is made available in an AI-friendly format for machine learning-based analysis. Linearis Labs can also perform data analysis with state-of-the-art machine learning algorithms.